Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

An Evolving Treatment Landscape for Inflammatory Disease: Involving Patients in the Discussion of Biosimilars

Premiere Date: Thursday, August 31, 2017

This activity offers CE credit for:

1. Physicians (CME)
2. Pharmacists (ACPE)
3. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Friday, August 31, 2018
Note: Credit Is No Longer Available

Faculty

Leonard H. Calabrese, DO (Moderator) Professor of Medicine Vice Chair, Department of Rheumatic & Immunologic Disease Cleveland Clinic Lerner College of Medicine of Case Western Reserve University R.J. Fasenmyer Chair of Clinical Immunology Cleveland Clinic Foundation Cleveland, OH

Russell D. Cohen, MD, FACG, AGAF  Professor of Medicine, Pritzker School of Medicine Director, Inflammatory Bowel Disease Center Co-Director, Advanced IBD Fellowship Program University of Chicago Medicine Chicago, IL

Edward Li, PharmD, MPH, BCOP   Professor University of New England College of Pharmacy Portland, ME

Statement of Need

Biologic agents are highly effective against inflammatory diseases, but may be restricted by many healthcare plans due to cost. Biosimilars offer a potential solution as a cost-effective alternative to biologic agents. Biosimilars have been available in Europe since 2005. In the United States, the first biosimilar monoclonal antibody, infliximab, was approved for rheumatoid arthritis (RA), adult ulcerative colitis (UC), psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis (AS), and adult and pediatric Crohn’s disease (CD).

Biosimilars are expected to have biologic activity similar to that of existing, approved biopharmaceuticals and comparable efficacy and safety based on a full assessment that includes analytical, preclinical, pharmacokinetics (PK), pharmacodynamics (PD), and clinical studies.”¹ With any new treatment, clinicians must be able to educate patients on the differences and similarities between biosimilars and generic agents.

In this CME Outfitters Snack, expert faculty will discuss the differences between biosimilars and generic agents, costs, and reimbursement. Further, this engaging program features the patient voice. Learners will hear directly from patients with inflammatory diseases and the education they have received on biosimilars.

Reference:
1. Kay J. A primer on biosimilars: how do biosimilars compare with reference biologics and generics? Medscape Website. http://www.medscape.org/viewarticle/837696.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Distinguish biosimilars from generic agents in the management of inflammatory diseases.
• Summarize interchangeability of biosimilars with reference biologics and how it impacts clinical practice.

Financial Support

Supported by an educational grant from Pfizer Inc.

Target Audience

Physicians, pharmacists, and physician assistants treating patients with inflammatory diseases

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 Credit^TM through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)^TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.05 CEUs) Universal Activity Number:
0376-0000-17-035-H01-P

Type: knowledge-based

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit^TM from organizations accredited by the Accreditation Council for Continuing Medical Education.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST22288 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Calabrese reports that he is a consultant for AbbVie Inc.; Centecor Biopharmaceutical; GlaxoSmithKline; Horizon Pharma; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; and UCB, Inc.

Dr. Cohen reports that he is serves as consultant / advisory / scientific advisory board for AbbVie Inc.; Celgene Corporation; Eli Lilly and Company; Hospira, Inc.; Janssen Research & Development, LLC (Johnson & Johnson / Centocor); Pfizer Inc.; Sandoz Biopharmaceuticals; Takeda Pharmaceuticals U.S.A., Inc. and UCB, Inc. He is the principal investigator in clinical trials for AstraZeneca; Celgene Corporation; Gilead Sciences, Inc.; Medimmune; Mesoblast Ltd.; Osiris Therapeutics, Inc.; Pfizer Inc.; Receptos, Inc.; RedHill Biopharma; Sanofi-Aventis and UCB, Inc. He serves on speakers bureau for AbbVie Inc. and Takeda Pharmaceuticals U.S.A., Inc. He has disclosed his spouse is on the board of directors for Protein Sciences Corporation; Tokai Pharmaceuticals, Inc.; Vital Therapies, Inc. and CytRx Corporation.

Dr. Li reports that he serves on speakers bureau for Apobiologix and Pfizer Inc. He serves as consultant for Mylan and Pfizer Inc.

Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.

Daniela V. DiBiase, MS (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).